L-type calcium channel blockers and parkinson disease in Denmark

Annals of Neurology

Volumn 67, Issue 5, 2010, Pages 600-606

  Ritz, Beate ^a   Rhodes, Shannon L ^a   Qian, Lei ^a   Schernhammer, Eva ^b   Olsen, Jørgen H ^c   Friis, Søren ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c INSTITUTE OF CANCER EPIDEMIOLOGY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANGIOTENSIN II ANTAGONIST; ANTIPARKINSON AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIHYDROPYRIDINE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FELODIPINE; ISRADIPINE; L TYPE CALCIUM CHANNEL BLOCKING AGENT; LACIDIPINE; LERCANIDIPINE; NICARDIPINE; NIFEDIPINE; NIMODIPINE; NITRENDIPINE; UNCLASSIFIED DRUG; VERAPAMIL;

AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; CONTROLLED STUDY; DENMARK; DOSE RESPONSE; DRUG BIOAVAILABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PRESCRIPTION; PRIORITY JOURNAL; RISK REDUCTION;

AGED; AGED, 80 AND OVER; AMLODIPINE; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; COMMUNITY HEALTH PLANNING; DENMARK; DIHYDROPYRIDINES; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; OUTPATIENTS; PARKINSON DISEASE; PRESCRIPTION DRUGS; REGISTRIES; RETROSPECTIVE STUDIES;

EID: 77951735527     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.21937     Document Type: Article

References (27)

1. Braak H, Del Tredici K. Nervous system pathology in sporadic Parkinson disease [invited article]. Neurology 2008;70:1916-1925.
2. Nedergaard S, Flatman JA, Engberg I. Nifedipine- and omega-conotoxin- sensitive Ca2+ conductances in guinea-pig substantia nigra pars compacta neurones. J Physiol 1993;466:727-747. (Pubitemid 23225251)
3. Surmeier DJ. Calcium, ageing, and neuronal vulnerability in Parkinson's disease. Lancet Neurol 2007;6:933-938. (Pubitemid 47405004)
4. Surmeier DJ. A lethal convergence of dopamine and calcium. Neuron 2009;62:163-164.
5. Henchcliffe C, Beal MF. Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis. Nat Clin Pract Neurol 2008;4:600-609.
6. Danielson SR, Andersen JK. Oxidative and nitrative protein modifications in Parkinson's disease. Free Radic Biol Med 2008;44:1787-1794.
7. Kupsch A, Sautter J, Schwarz J, et al. 1-Methyl-4-phenyl-1,2,3,6- tetrahydropyridine-induced neurotoxicity in non-human primates is antagonized by pretreatment with nimodipine at the nigral, but not at the striatal level. Brain Res 1996;741:185-196.
8. Ton TG, Heckbert SR, Longstreth WT Jr, et al. Calcium channel blockers and beta-blockers in relation to Parkinson's disease. Parkinsonism Relat Disord 2007;13:165-169.
9. Becker C, Jick SS, Meier CR. Use of antihypertensives and the risk of Parkinson disease. Neurology 2008;70:1438-1444. (Pubitemid 351521937)
10. Louis ED, Benito-Leon J, Bermejo-Pareja F. Antihypertensive agents and risk of Parkinson's disease, essential tremor and dementia: a population-based prospective study (NEDICES). Neuroepidemiology 2009;33:286-292.
11. Uchida S, Yamada S, Nagai K, et al. Brain pharmacokinetics and in vivo receptor binding of 1,4-dihydropyridine calcium channel antagonists. Life Sci 1997;61:2083-2090. (Pubitemid 27478835)
12. Andersen TF, Madsen M, Jorgensen J, et al. The Danish National Hospital Register. A valuable source of data for modern health sciences. Dan Med Bull 1999;46:263-268.
13. Gaist D, Sorensen HT, Hallas J. The Danish prescription registries. Dan Med Bull 1997;44:445-448.
14. World Health Organization Collaborating Center for Drug Statistics Methodology. ATC classification index with DDDs. Oslo, Norway: World Health Organization Collaborating Center for Drug Statistics Methodology, 2003.
15. Charlson ME, Sax FL, MacKenzie CR, et al. Morbidity during hospitalization: can we predict it? J Chronic Dis 1987;40:705-712.
16. Munoz A, Rey P, Guerra MJ, et al. Reduction of dopaminergic degeneration and oxidative stress by inhibition of angiotensin converting enzyme in a MPTP model of parkinsonism. Neuropharmacology 2006;51:112-120. (Pubitemid 43912233)
17. Grammatopoulos TN, Jones SM, Ahmadi FA, et al. Angiotensin type 1 receptor antagonist losartan, reduces MPTP-induced degeneration of dopaminergic neurons in substantia nigra. Mol Neurodegener 2007;2:1.
18. Lyons KE, Pahwa R. Pharmacotherapy of essential tremor: an overview of existing and upcoming agents. CNS Drugs 2008;22:1037-1045.
19. Goldstein DS. Dysautonomia in Parkinson's disease: neurocardiological abnormalities. Lancet Neurol 2003;2:669-676. (Pubitemid 37311320)
20. Ascherio A, Tanner CM. Use of antihypertensives and the risk of Parkinson disease. Neurology 2009;72:578-579. (Pubitemid 47047999)
21. Mason RP. Atheroprotective effects of long-acting dihydropyridine-type calcium channel blockers: evidence from clinical trials and basic scientific research. Cerebrovasc Dis 2003;16(suppl 3):11-17.
22. Mason RP, Campbell SF, Wang SD, Herbette LG. Comparison of location and binding for the positively charged 1,4-dihydropyridine calcium channel antagonist amlodipine with uncharged drugs of this class in cardiac membranes. Mol Pharmacol 1989;36:634-640.
23. Yoshida H, Ayaori M, Suzukawa M, et al. Effects of Caantagonists on oxidative susceptibility of low density lipoprotein (LDL). Hypertens Res 1995;18:47-53.
24. Tomassoni D, Lanari A, Silvestrelli G, et al. Nimodipine and its use in cerebrovascular disease: evidence from recent preclinical and controlled clinical studies. Clin Exp Hypertens 2008;30:744-766.
25. Chan CS, Guzman JN, Ilijic E, et al. 'Rejuvenation' protects neurons in mouse models of Parkinson's disease. Nature 2007;447:1081-1086.
26. Kupsch A, Gerlach M, Pupeter SC, et al. Pretreatment with nimodipine prevents MPTP-induced neurotoxicity at the nigral, but not at the striatal level in mice. Neuroreport 1995;6:621-625.
27. Mosharov EV, Larsen KE, Kanter E, et al. Interplay between cytosolic dopamine, calcium, and alpha-synuclein causes selective death of substantia nigra neurons. Neuron 2009;62:218-229.